Genenta Science’s (GNTA) Buy Rating Reaffirmed at HC Wainwright

Genenta Science (NASDAQ:GNTA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $25.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 496.66% from the company’s current price.

Genenta Science Stock Up 2.7 %

Shares of GNTA traded up $0.11 during mid-day trading on Wednesday, reaching $4.19. The company had a trading volume of 1,022 shares, compared to its average volume of 8,218. Genenta Science has a fifty-two week low of $2.20 and a fifty-two week high of $5.87. The firm has a fifty day simple moving average of $4.13 and a 200-day simple moving average of $3.66.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. bought a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned approximately 1.10% of Genenta Science at the end of the most recent quarter. Hedge funds and other institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.